BriaCell to Present Positive Clinical Data for Bria-IMT and Preclinical Data for Next Generation Bria-OTS+ Personalized Immunotherapy at the 2026 AACR Conference Biotech Investing
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain Life Science Investing
Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204 Life Science Investing
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug in Atopic Dermatitis Life Science Investing
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants Life Science Investing
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting Life Science Investing
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Life Science Investing
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
